Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluating the Impact of Neoadjuvant Chemotherapy on the Peripheral Blood Immune Phenotype in Patients With Operable Breast Cancer (ENHANCE)

NCT04897009 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT04897009
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04897009 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluating the Impact of Neoadjuvant Chemotherapy on the Peripheral Blood Immune Phenotype in Patients With Operable Breast Cancer (ENHANCE)
Lead sponsor
Mayo Clinic
Phase
Observational
Overall status
Active, not recruiting
Start date
June 9, 2021
Completion date
June 8, 2028
Enrollment
38 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

invasive breast carcinoma